$18.66
-0.10-0.53%
Last update: Nov 11, 4:00 PM
Cue Biopharma Inc (CUE) Stock Price, Quote, News & History
CUENASDAQ
Cue Biopharma reports Phase 2 CUE-221 trial results in chronic hives, showing strong efficacy and favorable safety.
You can purchase shares of Cue Biopharma (NASDAQ:CUE) through any online brokerage.
Other companies in Cue Biopharma’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Cue Biopharma has a consensus price target of $126.63.
The stock price for Cue Biopharma (NASDAQ: CUE) is $20 last updated November 10, 2026 at 4:47 AM EST.
There are no upcoming dividends for Cue Biopharma.
Cue Biopharma does not have any upcoming earnings scheduled.
There is no upcoming split for Cue Biopharma.
Cue Biopharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an...
